Related references
Note: Only part of the references are listed.Efficacy of Immunobiologic and Small Molecule Inhibitor Drugs for Psoriasis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
Andre Vicente Esteves de Carvalho et al.
DRUGS IN R&D (2017)
Shrinking the Psoriasis Assessment Gap: Early Gene-Expression Profiling Accurately Predicts Response to Long-Term Treatment
Joel Correa da Rosa et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2017)
TNF-α Antagonist and Vascular Inflammation in Patients with Psoriasis Vulgaris: A Randomized Placebo-Controlled Study
Robert Bissonnette et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2017)
Prediction of 30-year cardiovascular disease risk in psoriatic population
C. Buligan et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2017)
Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial
Kristin K. Jorgensen et al.
LANCET (2017)
Assays for Infliximab Drug Levels and Antibodies: AMatter of Scales and Categories
L. I. Bader et al.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2017)
Association Between Skin and Aortic Vascular Inflammation in Patients With Psoriasis A Case-Cohort Study Using Positron Emission Tomography/Computed Tomography
Amit K. Dey et al.
JAMA CARDIOLOGY (2017)
Association Between Inflammatory Skin Disease and Cardiovascular and Cerebrovascular Co-Morbidities in US Adults: Analysis of Nationwide Inpatient Sample Data
Michael C. Kwa et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2017)
Coronary Plaque Characterization in Psoriasis Reveals High-Risk Features That Improve After Treatment in a Prospective Observational Study
Joseph B. Lerman et al.
CIRCULATION (2017)
Comparing Originator Biologics and Biosimilars: A Review of the Relevant Issues
Corrado Blandizzi et al.
CLINICAL THERAPEUTICS (2017)
Circulating T-helper 17 cells and associated cytokines in psoriasis
S. Chhabra et al.
CLINICAL AND EXPERIMENTAL DERMATOLOGY (2016)
A Comprehensive Overview on Biosimilars
Vishruti Kadam et al.
CURRENT PROTEIN & PEPTIDE SCIENCE (2016)
Cytometry by time-of-flight immunophenotyping identifies a blood Sjogren's signature correlating with disease activity and glandular inflammation
Michael Mingueneau et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2016)
Impaired. function of regulatory T cells in patients with psoriasis is mediated by phosphorylation of STAT3
Luting Yang et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2016)
An optimized multiplex flow cytometry protocol for the analysis of intracellular signaling in peripheral blood mononuclear cells
Richard Davies et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2016)
Downmodulation of key inflammatory cell markers with a topical Janus kinase 1/2 inhibitor
N. Punwani et al.
BRITISH JOURNAL OF DERMATOLOGY (2015)
The Immunopathogenesis of Psoriasis
Jaehwan Kim et al.
DERMATOLOGIC CLINICS (2015)
Scientific rationale behind the development and approval of biosimilar infliximab (CT-P13) in Europe
Ulf Mueller-Ladner et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2015)
Down-regulation of the Th1, Th17, and Th22 pathways due to anti-TNF-α treatment in psoriasis
Li Luan et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2015)
The immunogenetics of Psoriasis: A comprehensive review
Jamie L. Harden et al.
JOURNAL OF AUTOIMMUNITY (2015)
Immunogenicity of Biotherapy Used in Psoriasis: The Science Behind the Scenes
Denis Jullien et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2015)
Association with Genetic Variants in the IL-23 and NF-kappa B Pathways Discriminates between Mild and Severe Psoriasis Skin Disease
Pernilla Nikamo et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2015)
Chronic inflammatory diseases: Do immunological patterns drive the choice of biotechnology drugs? A critical review
Silvano Sozzani et al.
AUTOIMMUNITY (2014)
Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity
P. H. Schafer et al.
CELLULAR SIGNALLING (2014)
Factors affecting response to biologic treatment in psoriasis
Jacek Karczewski et al.
DERMATOLOGIC THERAPY (2014)
IL-17 Induces Inflammation-Associated Gene Products in Blood Monocytes, and Treatment with Ixekizumab Reduces Their Expression in Psoriasis Patient Blood
Claire Q. F. Wang et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2014)
Biomarkers in psoriasis and psoriatic arthritis
Federica Villanova et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study
Dae Hyun Yoo et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study
Won Park et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Markers of systemic inflammation in psoriasis: a systematic review and meta-analysis
E. A. Dowlatshahi et al.
BRITISH JOURNAL OF DERMATOLOGY (2013)
Studies of Jak/STAT3 expression and signalling in psoriasis identifies STAT3-Ser727 phosphorylation as a modulator of transcriptional activity
Rosa M. Andres et al.
EXPERIMENTAL DERMATOLOGY (2013)
IκB kinase regulation of the TPL-2/ERK MAPK pathway
Thorsten Gantke et al.
IMMUNOLOGICAL REVIEWS (2012)
Th1, Th2, Th17 and Regulatory T Cell Pattern in Psoriatic Patients: Modulation of Cytokines and Gene Targets Induced by Etanercept Treatment and Correlation with Clinical Response
P. Quaglino et al.
DERMATOLOGY (2011)
Anti-cytoldne therapies for psoriasis
Kristine E. Nograles et al.
EXPERIMENTAL CELL RESEARCH (2011)
Stat3 as a Therapeutic Target for the Treatment of Psoriasis: A Clinical Feasibility Study with STA-21, a Stat3 Inhibitor
Ken Miyoshi et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2011)
Mechanisms and functions of p38 MAPK signalling
Ana Cuadrado et al.
BIOCHEMICAL JOURNAL (2010)
Circulating Th17, Th22, and Th1 Cells Are Increased in Psoriasis
Shinji Kagami et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2010)
New Insights in the Immunologic Basis of Psoriasis
Kristine E. Nograles et al.
SEMINARS IN CUTANEOUS MEDICINE AND SURGERY (2010)
Mechanisms of Disease: Psoriasis.
Frank O. Nestle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
p38MAPK: stress responses from molecular mechanisms to therapeutics
Lydia R. Coulthard et al.
TRENDS IN MOLECULAR MEDICINE (2009)
STATs in cancer inflammation and immunity: a leading role for STAT3
Hua Yu et al.
NATURE REVIEWS CANCER (2009)
Induction of IL-17+ T cell trafficking and development by IFN-γ:: Mechanism and pathological relevance in psoriasis
Ilona Kryczek et al.
JOURNAL OF IMMUNOLOGY (2008)
Pathogenesis and therapy of psoriasis
Michelle A. Lowes et al.
NATURE (2007)
Fluorescent cell barcoding in flow cytometry allows high-throughput drug screening and signaling profiling
PO Krutzik et al.
NATURE METHODS (2006)
Seven-transmembrane receptor signalling and ERK compartmentalization
Christopher J. Caunt et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2006)
Biology of tumor necrosis factor-α -: implications for psoriasis
AJG Schottelius et al.
EXPERIMENTAL DERMATOLOGY (2004)
Analysis of protein phosphorylation and cellular signaling events by flow cytometry: techniques and clinical applications
PO Krutzik et al.
CLINICAL IMMUNOLOGY (2004)
Intracellular phospho-protein staining techniques for flow cytometry: Monitoring single cell signaling events
PO Krutzik et al.
CYTOMETRY PART A (2003)
Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes
CN Ellis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
